Life Sciences

BioMedix receives FDA warning letter

Device Regulation Alert: Safety, Compliance and Reimbursement News, January 3, 2008

BioMedix Vascular Solutions failed to follow current Good Manufacturing Practices at its St. Paul, MN, facility that manufactures the PADnet+ noninvasive cardiovascular blood flow monitoring system, according to an FDA warning letter.

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   
    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Complete Guide to Lab Safety, 3rd Ed.

    The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...

Most Popular